S Science Co Debt/EBITDA
The Total Debt to EBITDA Ratio of S Science Co (5721.T) as of Oct 8, 2026 is -5.17. In the previous year, Total Debt to EBITDA Ratio was 0.01 — a change of -69,641.01% (lower).
Get this data via API
Financial Data API
Debt/EBITDA
-5.17
YoY
-69,641.01%
Last updated:
The S Science Co Debt/EBITDA history
3 Years
10 Years
25 Years
Max
| YEAR | Debt/EBITDA | YoY |
|---|---|---|
| -5.17 | -69,641.01% | |
| 0.01 | -128.68% | |
| -0.03 | +114.49% | |
| -0.01 | -8.36% | |
| -0.01 | +20.10% | |
| -0.01 | +120.99% | |
| -0.00 | +1,015.26% | |
| -0.00 | -98.56% | |
| -0.03 | -191.18% | |
| 0.03 | -102.27% | |
| -1.50 | -36.56% | |
| -2.37 | — |
S Science Co Stock analysis
Frequently Asked Questions about S Science Co stock
Total Debt to EBITDA Ratio of S Science Co is -5.17 in 2026.
Total Debt to EBITDA Ratio of S Science Co changed from 0.01 to -5.17, representing a -69,641.01% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio S Science Co since 2006 – with annual values, charts, and detailed analysis.
Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's S Science Co with sector peers and the industry average to assess whether it is attractive.
Leverage — S Science Co
All Key Metrics — S Science Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth